[18F]FDG与[18F]PSMA-1007 PET/CT联合预测前列腺癌分期时肿瘤侵袭性及术后生化失败
前瞻性研究纳入42例前列腺癌患者的42个索引肿瘤,术前行[18F]PSMA-1007和[18F]FDG PET/CT后行根治性前列腺切除术并随访中位26个月。所有肿瘤均被[18F]PSMA-1007检出而仅15个被[18F]FDG检出,[18F]FDG阳性肿瘤多为导管优势型且术后生化失败率更高。
要点
- [18F]PSMA-1007 PET/CT检出全部42个索引肿瘤,[18F]FDG仅检出15个。
- [18F]FDG阳性肿瘤多为导管优势型且[18F]PSMA-1007 SUVmax更低。
- [18F]FDG阳性患者术后生化失败率53.3%,阴性者14.8%。
核心结论
- [18F]PSMA-1007 PET/CT在检测原发性前列腺癌方面优于[18F]FDG PET/CT。
- [18F]FDG摄取的肿瘤与更大体积、导管优势型相关,且可能在分期时发生转移、术后出现生化失败。
研究设计与样本
- 前瞻性研究纳入42例患者的42个索引肿瘤(27个腺泡型、15个导管优势型),均行[18F]PSMA-1007和[18F]FDG PET/CT及根治性前列腺切除术。
- 所有患者随访中位26个月,每3个月测血清前列腺特异性抗原以评估生化失败。
- 统计分析采用单因素方差分析、Tukey多重比较检验和Fisher精确检验。
主要发现
- 全部42个索引肿瘤在[18F]PSMA-1007 PET/CT上检出,而[18F]FDG PET/CT仅检出15个(62.3% vs. 37.7%,p < 0.0001)。
- 高Gleason评分肿瘤(GS 8-10)的[18F]PSMA-1007 SUVmax高于GS 6-7(20.1 vs. 12.1,p < 0.05)。
- [18F]FDG摄取肿瘤多为导管优势型(腺泡优势型4/27;导管优势型11/15,p < 0.001),且[18F]PSMA-1007 SUVmax低于无[18F]FDG摄取肿瘤(16.58 vs. 11.19,p < 0.001)。
- 16.6%(7/42)的患者为pStage IV,其原发肿瘤为[18F]FDG阳性。
- [18F]FDG阴性肿瘤患者生化失败率为14.8%(4/27),[18F]FDG阳性肿瘤患者为53.3%(8/15)(p = 0.013)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has limitations in prostate cancer (PCa) detection owing to low glycolysis in the primary tumour. Recently, prostate-specific membrane antigen (PSMA) PET/CT has been useful for biochemical failure detection and radioligand therapy (RLT) guidance. However, few studies have evaluated its use in primary prostate tumours using PSMA and [18F]FDG PET/CT. This study aimed to evaluate [18F]PSMA-1007 and [18F]FDG PET/CT for primary tumour detection and understand the association of metabolic heterogeneity with clinicopathological characteristics at staging and postoperatively. METHOD: This prospective study included 42 index tumours (27 acinar and 15 ductal-dominant) in 42 patients who underwent [18F]PSMA-1007 and [18F]FDG PET/CT and subsequent radical prostatectomy. All patients were followed for a median of 26 mo, and serum prostate-specific antigen levels were measured every 3 mo to evaluate biochemical failure. One-way analysis of variance, Tukey's multiple comparison test, and Fisher's exact test were performed. RESULTS: All 42 index tumours were detected on [18F]PSMA-1007 PET/CT, whereas only 15 were detected on [18F]FDG PET/CT (62.3% vs. 37.7%, p < 0.0001). A high SUVmax for [18F]PSMA-1007 was observed in tumours with high Gleason scores (GS 6-7 vs. GS 8-10; 12.1 vs. 20.1, p < 0.05). Tumours with [18F]FDG uptake were mostly ductal dominant (acinar-dominant 4/27; ductal-dominant; 11/15, p < 0.001), with lower [18F]PSMA-1007 uptake than tumours without [18F]FDG uptake (SUVmax 16.58 vs. 11.19, p < 0.001). There were 16.6% (7/42) of patients with pStage IV in whom the primary tumours were [18F]FDG positive. Biochemical failure was observed in 14.8% (4/27) of patients with [18F]FDG negative tumours but in 53.3% (8/15) of patients with [18F]FDG positive tumours (p = 0.013). CONCLUSIONS: [18F]PSMA-1007 PET/CT was superior to [18F]FDG PET/CT in detecting primary PCa. In contrast, tumours with [18F]FDG uptake are associated with larger size, a ductal-dominant type, and likely to undergo metastasis at staging and biochemical failure postoperatively.
引用
- Kim J, Lee S, Kim D, et al. Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 38200396. doi:10.1007/s00259-023-06585-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。